Navigation Links
Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
Date:8/4/2010

JUPITER, Fla., Aug. 4 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic") announced today that the United States District Court for the Southern District of Florida has approved the final resolution of the consolidated stockholder class action lawsuit, Miller v. Dyadic International, Inc. et al, and dismissed the lawsuit with prejudice.

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20091214/DYADICLOGO )

The lawsuit initially filed in October 2007 asserted class action claims under federal securities laws based on allegations of misstatements and omissions by Dyadic and certain of its current and former officers and directors arising out of alleged improprieties at Dyadic's Asian subsidiaries.  As reported in Dyadic's latest consolidated financial statements, Dyadic established a cash reserve in connection with the class action lawsuit which adequately covers the costs associated with resolving this matter.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "We are pleased to put this matter behind us so we can continue focusing on growing our business through the ongoing sale of enzymes and the monetization of our C1 platform technology through potential licensing arrangements and other collaborations."

About Dyadic

Dyadic is a global biotechnology company that uses its patented and proprietary technologies for the discovery, development, manufacture and sale of enzyme products and solutions to address the needs of the bioenergy, biopharmaceutical and industrial enzyme markets. Please visit Dyadic's website at www.dyadic.com

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International Engages The Abraham Group as Strategic Advisor
2. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
3. Dyadic International Strengthens Management Team
4. Dyadic International Extends Collaboration With The Scripps Research Institute
5. Renhuang Receives AAA(1) Rating from Chinese Academy of International Trade & Economic Cooperation of Ministry of Commerce
6. SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents
7. FRC Systems International State-of-the-art Industrial Wastewater Treatment Systems
8. Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition
9. Bacterin International Appoints Three New Members to Its Board of Directors
10. THE PLANNING SHOP international Announces Oncology Business Unit
11. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new ... specialty pharmacy resource–user-centric, story-driven, knowledge-based and mobile-friendly. Visit ... ... ... "The goal was ...
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  In ... key role for a host of launch activities including ... importance of this launch activity is especially high in ... specialists. Best Practices and the Role of ... will help companies focused on oncology therapies find better ...
(Date:2/4/2016)... 2016 - New FDA action date of ... FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast has ... indicated for the treatment of signs and symptoms of dry eye ... potential to be the only product approved in the U.S. in the past decade indicated ...
(Date:2/4/2016)... MONMOUTH JUNCTION, N.J. , Feb. 4, 2016 ... critical care immunotherapy leader commercializing its flagship CytoSorb® ... and cardiac surgery patients around the world, announced ... PhD, will present at the Source Capital Group,s ... overview and update on the company.  ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate Growth ... analysis of the digital and computed radiography markets in ... , and Indonesia (TIM). It ... market size, as well as regional market drivers and ... discusses market penetration and market attractiveness, both for digital ...
(Date:2/1/2016)... , February 1, 2016 Rising ... to drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new ... market size through 2020   ... coupled with new technological advancements to drive global touchfree ...
Breaking Biology News(10 mins):